Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
Cristina Valero(Memorial Sloan Kettering Cancer Center), Luc G.T. Morris(Memorial Sloan Kettering Cancer Center), Nadeem Riaz(Memorial Sloan Kettering Cancer Center), Conall Fitzgerald(Memorial Sloan Kettering Cancer Center), Joris L. Vos(Memorial Sloan Kettering Cancer Center), Alan L. Ho(Memorial Sloan Kettering Cancer Center), Traci Pawlowski(Illumina (United States)), Catherine Y. Han(Memorial Sloan Kettering Cancer Center), Diego Chowell(Icahn School of Medicine at Mount Sinai), Lillian A. Boe(Memorial Sloan Kettering Cancer Center), Charlotte L. Zuur(Leiden University Medical Center), Li Liu(Illumina (United States)), Shannon Kaplan(Illumina (United States)), Mahdi Golkaram(Illumina (United States)), Abhinav Pandey(Memorial Sloan Kettering Cancer Center), Timothy A. Chan(Cleveland Clinic), Elizabeth S. Koh(Memorial Sloan Kettering Cancer Center), Mark Lee(Howard Hughes Medical Institute), David B. Solit(Memorial Sloan Kettering Cancer Center), Bin Xu(Memorial Sloan Kettering Cancer Center), Xin Pei(Memorial Sloan Kettering Cancer Center), Reith Sarkar(Memorial Sloan Kettering Cancer Center)
Cited by 31
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k